Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

SPACTORY SPACTORY, revolutionising pharmaceutical development and manufacturing through microgravity

Coordinator
Spacepharma R&d Israel Ltd, Israel
Runs
1 August 2024 to 30 September 2026
Status
Running
EU funding
€2.2m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101189238

What the project is doing

In the project's own words, from its summary on CORDIS.

Over 2,000 R&D experiments have been done in Space until now. Space near-zero gravity yields biochemical crystals orders of magnitude more defined, pure, uniform, and precise than in terrestial environments. The low-gravity accelerates the development and preclinical testing of complex molecules –e.g. proteins- and unleashes the potential of innovative high-value mAbs therapies, saving patient’s lives and improving their QoL.To make it real, after 11 space missions, SPACEPHARMA is committed to bringing the first mAbs factory to Space.

MOTI, the main SPACTORY building block, brings accessible, scalable, and affordable microgravity manufacturing controlled from Earth and able to fly in any satellite compatible with any launcher. For our customers, the pharma industry, it means shorter time to Space, faster market access and affordable drug development. For SPACEPHARMA, it is a paradigm shift from drug R&D to manufacturing. For EU, it means leading the spatial race in drug development.

Topics

Who is involved

OrganisationCityCountryRole
Spacepharma R&d Israel LtdHerzliya PituachIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI